iTeos Therapeutics, Inc. (NASDAQ:ITOS) Major Shareholder Bioventures 2014 L.P. Mpm Sells 24,303 Shares

iTeos Therapeutics, Inc. (NASDAQ:ITOS) major shareholder Bioventures 2014 L.P. Mpm sold 24,303 shares of iTeos Therapeutics stock in a transaction dated Monday, September 20th. The stock was sold at an average price of $27.49, for a total transaction of $668,089.47. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Bioventures 2014 L.P. Mpm also recently made the following trade(s):

  • On Friday, September 17th, Bioventures 2014 L.P. Mpm sold 45,698 shares of iTeos Therapeutics stock. The stock was sold at an average price of $28.82, for a total transaction of $1,317,016.36.
  • On Wednesday, September 15th, Bioventures 2014 L.P. Mpm sold 24,104 shares of iTeos Therapeutics stock. The stock was sold at an average price of $27.80, for a total transaction of $670,091.20.

Shares of ITOS stock opened at $26.81 on Tuesday. The stock has a market capitalization of $943.98 million, a P/E ratio of -13.08 and a beta of 2.43. The company has a 50 day moving average price of $26.16 and a 200 day moving average price of $26.37. iTeos Therapeutics, Inc. has a fifty-two week low of $17.43 and a fifty-two week high of $47.61.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Thursday, August 12th. The company reported ($0.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.34). Equities analysts forecast that iTeos Therapeutics, Inc. will post 3.22 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in the stock. RTW Investments LP grew its holdings in shares of iTeos Therapeutics by 157.2% in the first quarter. RTW Investments LP now owns 2,762,791 shares of the company’s stock valued at $94,432,000 after purchasing an additional 1,688,625 shares in the last quarter. BlackRock Inc. grew its holdings in shares of iTeos Therapeutics by 44.0% in the first quarter. BlackRock Inc. now owns 1,533,322 shares of the company’s stock valued at $52,409,000 after purchasing an additional 468,576 shares in the last quarter. Alliancebernstein L.P. grew its holdings in iTeos Therapeutics by 15.8% during the 2nd quarter. Alliancebernstein L.P. now owns 1,355,078 shares of the company’s stock worth $34,758,000 after acquiring an additional 185,077 shares in the last quarter. Citadel Advisors LLC grew its holdings in iTeos Therapeutics by 94.6% during the 2nd quarter. Citadel Advisors LLC now owns 994,396 shares of the company’s stock worth $25,506,000 after acquiring an additional 483,398 shares in the last quarter. Finally, Citigroup Inc. grew its holdings in iTeos Therapeutics by 1,125.1% during the 2nd quarter. Citigroup Inc. now owns 432,484 shares of the company’s stock worth $11,093,000 after acquiring an additional 397,181 shares in the last quarter. Hedge funds and other institutional investors own 83.69% of the company’s stock.

ITOS has been the topic of a number of research analyst reports. Zacks Investment Research raised shares of iTeos Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 30th. SVB Leerink reduced their price target on shares of iTeos Therapeutics from $56.00 to $55.00 and set an “outperform” rating on the stock in a research note on Friday, August 13th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, iTeos Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $47.25.

About iTeos Therapeutics

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.

See Also: Stock Symbol

Insider Buying and Selling by Quarter for iTeos Therapeutics (NASDAQ:ITOS)

Receive News & Ratings for iTeos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iTeos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.